# BPC-157 TB-500 FAQ: 25 Questions on the Wolverine Blend, Answered and Cited

> BPC-157 TB-500 questions answered from the record — what the blend is, the two mechanisms, half-life, dosage context, synergy, side effects, and the FDA 503A legal status. Direct, cited answers.

Twenty-five direct answers on the Wolverine blend — identity, mechanism, recovery, dosage context, safety, and legal status — each tied to the cited record.

## Frequently asked questions about the BPC-157 TB-500 blend

These are the most common BPC-157 TB-500 questions, each answered from the cited record — the single-compound studies, the recent reviews, and the FDA regulatory references. Where the answer is a number, it carries its citation. Where the honest answer is 'no controlled data exist,' it says so plainly rather than reaching for a forum protocol.

### What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 (a synthetic 15-amino-acid gastric-juice fragment) and TB-500 (the synthetic Ac-LKKTETQ fragment of Thymosin Beta-4), discussed as a tissue-repair 'stack' [3][5]. It is not a single chemical entity or an approved product; the name is community shorthand, not a defined formulation.

### What is BPC-157 and TB-500?
BPC-157 is a pentadecapeptide (GEPPPGKPADDAGLV) reported to be pro-angiogenic via a VEGFR2-Akt-eNOS pathway [2]; TB-500 is an N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4 [3][5]. They are two distinct synthetic research peptides, combined in the blend.

### What is the BPC-157 and TB-500 blend used for in research?
The individual components have been studied in animal models of tendon, ligament, muscle, and soft-tissue repair and in cell models of angiogenesis and cell migration [1][2][4]. The blend itself has no controlled studies; it is described as a tissue-repair pairing on a theoretical basis [6].

### Why are BPC-157 and TB-500 combined (the Wolverine stack)?
The rationale is complementary mechanisms: BPC-157 supplies a local angiogenic and cytoprotective signal (VEGFR2-Akt-eNOS) [2], while TB-500 / Thymosin Beta-4 supplies an actin-sequestration signal that regulates cell migration [3]. The pairing's 'synergy' is a theoretical extrapolation, not a controlled-study finding [6].

### Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither component is FDA-approved for human use and the blend has no approved indication. Both are FDA 503A Category 2 bulk substances — the FDA identified them as potentially presenting significant safety risks — restricting pharmacy compounding pending evaluation [9][10]. Both are prohibited by the World Anti-Doping Agency.

### What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid pentadecapeptide acting mainly through VEGFR2-Akt-eNOS angiogenesis, nitric-oxide modulation, and growth-hormone-receptor sensitization [2]. TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4 acting through 1:1 G-actin sequestration that regulates cell migration [3]. Different sizes, different proposed pathways.

### What is the latest research on BPC-157 and TB-500?
Recent reviews include a 2025 HSS Journal systematic review of BPC-157 (36 studies, only 1 human, no clinical safety data, no TB-500 or combination mention) [6], a 2025 narrative review treating BPC-157 as investigational [8], and a 2026 Sports Medicine review of unapproved peptides noting animal-model promise but scarce human safety data [7].

### What does TB-500 stand for and how does it relate to Thymosin Beta-4?
TB-500 is the synthetic N-acetylated heptapeptide Ac-LKKTETQ, corresponding to residues 17-23 — the actin-binding motif — of Thymosin Beta-4, a 43-amino-acid intracellular actin-sequestering protein [3][5]. Most efficacy data attributed to 'TB-500' were actually generated with full-length Thymosin Beta-4, not the 7-mer [4].

### Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for BPC-157 and TB-500 given together. The 2025 HSS Journal systematic review of BPC-157 does not mention TB-500 or combination use [6]. 'Synergy' is an extrapolation from two largely non-overlapping single-compound mechanisms [2][3].

### Are there human clinical trials on the BPC-157 + TB-500 combination?
There are no controlled human trials of the combination [6][7]. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies, and 'TB-500' human data are actually for full-length Thymosin Beta-4 (a 40-volunteer and an 84-volunteer Phase 1 IV study), not the 7-mer [4][5].

### Does the BPC-157 TB-500 blend help tendon and ligament injuries?
In animal models, BPC-157 accelerated healing of transected rat Achilles tendon (biomechanics, collagen organization) and improved ligament healing [1]; Thymosin Beta-4 also enhanced ligament healing in rats [4]. These are preclinical single-compound findings, not human or combination evidence.

### Does BPC-157 and TB-500 help muscle tears and recovery?
Preclinically, BPC-157 improved healing of crushed and detached muscle and the myotendinous junction in rats, and Thymosin Beta-4 recruits myoblasts to injured muscle [1][4]. A chronic Thymosin Beta-4 study in mdx mice increased regenerating fibers but did not improve strength — an honest counterpoint to the recovery narrative.

### How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it by capping both ends, preventing polymerization. X-ray crystallography of a Thymosin Beta-4-actin complex established this structural basis [3]; the regulated actin pool underlies cell migration and re-epithelialization.

### How does BPC-157 work compared to TB-500?
BPC-157 up-regulates VEGFR2 with downstream Akt-eNOS angiogenic signaling, modulates nitric oxide, and sensitizes tendon fibroblasts to growth hormone [2]; TB-500 works through G-actin sequestration and cytoskeletal remodeling [3]. They act through complementary but largely non-overlapping pathways.

### What is the half-life of BPC-157 and TB-500?
BPC-157's elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study. No validated human half-life exists for the TB-500 heptapeptide; human IV full-length Thymosin Beta-4 showed dose-proportional pharmacokinetics [4][5]. No validated half-life exists for the blend.

### How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Research peptides are supplied as lyophilized powder and reconstituted in bacteriostatic or sterile water, then refrigerated. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [5]. This is described for research handling, not as human-use guidance.

### How often should you inject BPC-157 and TB-500?
There is no validated injection schedule for the blend. Underlying animal studies used per-body-weight intraperitoneal dosing (e.g. BPC-157 ~10 µg/kg; full-length Thymosin Beta-4 in mg/kg ranges) [1][4]. Community 'loading then maintenance' protocols have no controlled-trial basis.

### What are the side effects of BPC-157 and TB-500?
There are no controlled human safety data for the blend [6][7]. A key theoretical concern is the pro-angiogenic and pro-migratory profile of Thymosin Beta-4, which is implicated in tumor metastasis and angiogenesis [4]; BPC-157's long-term human safety is unknown [8]. Reviews treat both as investigational.

### Does TB-500 cause cancer or promote tumor growth?
Thymosin Beta-4 is overexpressed in several cancers and has been implicated in metastasis and tumor angiogenesis — the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is a theoretical safety signal, not a demonstrated effect of the blend in humans.

### How do you cycle BPC-157 and TB-500?
Fixed-ratio vials (e.g. 10 mg + 10 mg) and 'loading then maintenance' cycles circulate in the community but have no basis in controlled human trials. A rat embolic-stroke study found Thymosin Beta-4 dosing non-monotonic — a high dose (18 mg/kg) gave no benefit [4] — undermining 'more is better' loading logic.

### Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
In animal and cell models, yes — by distinct routes: BPC-157 up-regulates VEGFR2 and increases vessel density and blood-flow recovery in ischemic muscle [2], while Thymosin Beta-4 promotes endothelial migration and angiogenesis [4]. This shared vascular thread is part of the combination rationale.

### Does the BPC-157 TB-500 blend help wound healing?
In a rat full-thickness wound model, Thymosin Beta-4 increased re-epithelialization, contraction, collagen, and angiogenesis, and BPC-157 shows broad cytoprotective wound activity [4]. These are preclinical single-compound results, not human or combination evidence.

### Is Wolverine legal?
Neither BPC-157 nor TB-500 is an FDA-approved drug, and the blend has no approved indication; both are FDA 503A Category 2 bulk substances, so pharmacy compounding under 503A is restricted pending the FDA's ongoing evaluation [9][10][11]. Both are WADA-prohibited in sport, and material sold outside that framework is unregulated.

### Can you get BPC-157 from a compounding pharmacy?
BPC-157 is an FDA 503A Category 2 bulk substance — the FDA identified it as potentially presenting significant safety risks, and it is not within the enforcement-discretion policy for 503A compounding [9][10]. It is on the scheduled July 23-24, 2026 PCAC agenda as a substance under evaluation for the 503A bulks list — a discussion, not a listing [11].

### What is the FDA 503A status of Wolverine?
The blend is not an approved drug. Both components — BPC-157 and the TB-500 fragment of Thymosin Beta-4 — are FDA 503A Category 2 bulk substances as of the September 29, 2023 update, excluded from routine compounding pending review, and both are on the scheduled July 2026 PCAC agenda for evaluation (a discussion, not a decision) [9][11].

---

A barely-there evidence ledger of the BPC-157 and TB-500 record — the few single-compound findings that hold set in one tier, the blend-level and access gaps left one tier down and in plain sight, with no clinic behind the page and nothing here dispensed.